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Abstract Age-related macular degeneration (AMD) is the
primary cause of blindness in developed countries, and is
the third leading cause worldwide. Emerging evidence
suggests that beside environmental and genetic factors,
epigenetic mechanisms, such as microRNA (miRNA)
regulation of gene expression, are relevant to AMD pro-
viding an exciting new avenue for research and therapy.
MiRNAs are short, non-coding RNAs thought to be
imperative for coping with cellular stress. Numerous
studies have analyzed miRNA dysregulation in AMD
patients, although with varying outcomes. Four studies
which profiled dysregulated circulating miRNAs in AMD
yielded unique sets, and there is only minimal overlap in
ocular miRNA profiling of AMD. Mouse models of AMD,
including oxygen-induced retinopathy and laser-induced
choroidal neovascularization, showed similarities to some
extent with miRNA patterns in AMD. For example, miR-
146a is an extensively researched miRNA thought to
modulate inflammation, and was found to be upregulated in
AMD mice and cellular systems, but also in human AMD
retinae and vitreous humor. Similarly, mir-17, miR-125b
and miR-155 were dysregulated in multiple AMD mouse
models as well as in human AMD plasma or retinae. These
miRNAs are thought to regulate angiogenesis, apoptosis,
phagocytosis, and inflammation. A promising avenue of
research is the modulation of such miRNAs, as the
phenotype of AMD mice could be ameliorated with
antagomirs or miRNA-mimic treatment. However, before
meaningful strides can be made to develop miRNAs as a
diagnostic or therapeutic tool, reproducible miRNA pro-
files need to be established for the various clinical out-
comes of AMD.
Key Points
Several studies of microRNA, small non-protein
coding RNA molecules, were conducted in blood
and vitreous humor of AMD patients, but revealed
few microRNAs consistently dysregulated in
multiple studies.
Similar profiling studies were reported in mouse
models of distinct AMD features and demonstrated
some similarities with the human AMD findings,
including miR-146a, miR-17, miR-125b, and
miR-155.
Alteration of the levels of these miRNA in mice
revealed an amelioration of the AMD-related
damage, providing a promise for novel therapeutic
approaches for this devastating blinding disease.
1 Introduction
1.1 MicroRNAs: An Historical Perspective
MicroRNAs (miRNAs) are 19-24 nucleotide non-coding
RNAs, which negatively regulate gene expression.
Although miRNAs were not discovered until 1993, the idea
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that non-coding RNA molecules could interfere with gene
expression, was first suggested in the late 1970s and early
1980s, when multiple groups found that exogenous
oligonucleotides complementary to ribosomal RNA inter-
fere with ribosome function [1–3].
Ironically, the motivation behind the project which
ultimately lead to the discovery of miRNAs had only little
to do with the field of noncoding RNAs or antisense gene
regulation, but instead started with the study of neural
development in microscopic worms [4, 5]. In the 1970s,
Brenner [6] discovered a line of mutant lin-4(e912)
Caenorhabditis elegans with remarkable developmental
timing defects [7]. The ‘‘adult’’ larvae contained many cell
types ordinarily only present during an early larval stage,
and were devoid of many of the cell types and morpho-
logical structures typical of wild-type adults [4, 8].
In 1984, Ferguson et al. [9] discovered a C. elegans
worm with nearly normal morphology in a culture of the
lin-4 strain, and determined that a previously unknown
gene, lin-14 was the responsible suppressor mutation.
Animals with null alleles of lin-14 were shown to have
developmental timing defects opposite to those of lin-4
[10]. These findings suggested an epistatic interaction
between lin-4 and lin-14, and it was theorized that lin-4
encodes a protein which negatively regulates lin-14 [5]. In
1993, almost four years after the initial findings, two arti-
cles were published in the same issue of the Cell journal
which elucidated the molecular relationship between lin-14
and lin-4. Lee et al. [4] showed that lin-4 is not a protein-
encoding gene, but instead a 22nt non-coding RNA tran-
script and a 60nt hairpin structure. The second study
reported that seven nucleotides in the 30 untranslated region
(UTR) of lin-14 are complementary to the lin-4 small
RNAs, and suggested that lin-4 downregulates lin-14
translation through RNA-mediated gene expression [11].
1.2 MiRNAs and Ocular Pathogenesis
It is difficult to understate the importance of miRNAs, as
they regulate proper cell growth, development, and dif-
ferentiation [12]. Much of the early work on miRNAs
focused on their roles in tissue and organ development
[4, 13]. In this context, loss of miRNA function produced
gross phenotypic defects, and their impact was unmistak-
able [13]. As technology advanced, researchers began
uncovering the function of miRNAs in the mature tissue of
higher eukaryotes. In recent years, the theory emerged that
miRNA in mature organisms and tissues tend not to affect
the primary function of cells, but are imperative for coping
with various forms of cellular and organismal stress
[13–16]. To date, miRNAs are thought to buffer against
fluctuations in gene expression due to either stochastic
modulation or environmental stress, in an effort to maintain
cellular homeostasis [13, 17–19]. To facilitate their func-
tion, miRNAs are specifically incorporated into the RNA-
induced silencing complex (RISC) and bind to transcripts
in the cytosol. This binding either results in the degradation
of the transcript by nucleases associated with the RIS
complex or lead to reduced translation speed by influencing
the ribosomal machinery.
As photoreceptors and retinal pigment epithelium (RPE)
cells of the retina must maintain their function under
exceptionally high rates of metabolism and protein syn-
thesis, there is arguably no system under more stress [13].
Specifically, in pathological conditions of the eye, the
intense stress overwhelms the cells’ coping mechanisms
resulting in photoreceptor death ultimately causing blind-
ness. This makes the retina a highly interesting organ to
elucidate the pathological repercussions of miRNA dys-
regulation in mature tissue.
1.3 Age-Related Macular Degeneration (AMD)
AMD is a complex disease of the central retina and the
primary cause of blindness in developed countries, as well
as the third leading cause worldwide [20]. Estimates put
the number of people suffering from the late stage of the
disease worldwide at 11 million by 2020 [21]. In a healthy
eye, light is transduced to a chemical signal by the highly
specialized photoreceptors, which have a multifaceted
support system. In AMD, the dysfunction of this support
system causes progressive damage to the photoreceptors,
and ultimately results in vision loss in one or both eyes
[22].
Although the pathogenesis of AMD is currently not
completely understood, the complex etiology has been
linked to cellular, biochemical, and molecular events and is
influenced by multiple components involving both envi-
ronmental factors and genetic predisposition [22–24].
Genome-wide association studies and large scale re-se-
quencing projects have identified a number of single
nucleotide variants (SNVs) enriched in complement and
complement-related genes that confer a strong risk for
AMD [25–28]. Recent efforts have increased the number of
independent genetic signals associated with AMD risk to
52 at 34 different loci [27], explaining around half of the
genomic heritability of the disease. Six out of those 34 loci
harbor one or more complement or complement-related
genes. Together, the known genetic risk factors point to the
involvement of oxidative stress, lipid metabolism, extra-
cellular matrix biology, inflammation and dysregulation of
the complement cascade and other immune responses in
the pathogenesis of the disease.
Early stages of AMD are characterized by an abnormal
RPE pigment distribution in the macula, and the formation
of drusen-containing lipids and an array of proteins in the
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space between the basal lamina of the RPE and the inner
collagenous layer of Bruch’s membrane [22, 29–31]. Early
AMD is usually asymptomatic, but may cause a modest
decline in visual acuity and function resulting in delayed
dark adaptation [22].
Early AMD can progress to late-stage AMD, charac-
terized by geographic atrophy (GA AMD) and choroidal
or, less common, retinal neovascularization (both forms
subsumed as NV AMD). GA AMD is defined by well-
demarcated areas of RPE atrophy, which is followed by
degeneration of the corresponding photoreceptors and
choroidal capillaries [32]. Disease progression in GA AMD
is usually slow, although it can result in significant visual
deficits in reading, night vision, and dark adaptation
[33, 34]. There is currently no approved or effective
treatment to prevent the onset or progression of GA
[24, 35].
The hallmark of NV AMD is the growth of new blood
vessels generally sprouting from the choroid, penetrating
the overlying Bruch’s membrane, and growing within the
subretinal pigment epithelium space or the subretinal space
[36, 37]. In NV AMD the growing neovascular membrane
is initially capillary-like [36], and these fenestrated and
friable vessels frequently leak serous fluid, lipid, and blood
into the retina and surrounding spaces. The neovascular-
ization is accompanied by the infiltration of macrophages
and other inflammatory, matrix metalloproteinases pro-
ducing cells, enabling the growing membrane to digest
through tissue planes [38]. Macrophages release a range of
other mediators, including pro-inflammatory and proan-
giogenic factors. At some point, the balance between
growth factors and inflammatory mediators shifts toward
an antiangiogenic, anti-proteolytic, and anti-migratory
state, and the CNV lesion becomes fibrosed [36, 37]. This
process is known as disciform scar formation, and is
associated with irreversible visual loss [36]. Untreated
patients with NV AMD experience a consistent, steady
deterioration in visual acuity over the first few years fol-
lowing onset of neovascularization, with 75 % of patients
reaching legal blindness within 3 years [39].
Choroidal neovascularization can be treated but not
cured with inhibitors of vascular endothelial growth factor
(VEGF) [40]. In the pathogenesis of NV AMD, increased
VEGF production is a defensive response by the tissue to
oxidative stress or hypoxia, triggering the proliferation of
newly formed blood vessels and damaging the retinal tis-
sues, especially the photoreceptors [41]. In the past several
years, the inhibition of VEGF has become the gold stan-
dard in the treatment of NV AMD, but is far from an ideal
therapy. Monthly injections of VEGF inhibitors are bur-
densome to patients and a major challenge to healthcare
systems worldwide [42]. Additionally, AMD patients with
NV exhibit a great deal of variability in response to anti-
VEGF treatments, some patients even lose visual acuity
during treatment [40, 43].
Despite advances in the prevention and treatment of the
disease, the number of afflicted patients is expected to
increase due to a rapidly growing elderly population [20].
In many cases, the damage is not contained to the pho-
toreceptors and RPE cells, the mental health of these
patients may also suffer. Depression affects 30 % of older
adults with visual impairment, and those with AMD seem
to be at particular risk with 39 % affected [44]. The mental
deterioration is thought to stem from the frustration and
hopelessness elderly patients can feel when the loss of
functional capacity becomes apparent [44]. In a national
opinion poll of US adults, when asked which disease is the
worst that could happen to them, African Americans and
Non-Hispanic Whites said that blindness was worse than
cancer and HIV/AIDS [45]. This underscores the urgent
need for an effective AMD treatment.
The purpose of this review is to inventory the work that
has been done to profile miRNA dysregulation in AMD,
and further summarize the miRNA work done in well-
established mouse models of AMD (Fig. 1). The question
arises whether miRNA-based approaches to treatment
could be feasible to ameliorate AMD-related tissue damage
in the retina and consequently to prevent vision impairment
or even blindness.
2 MiRNA and AMD
2.1 Circulating miRNA Profiles of AMD Patients
Show Inconsistencies
The function and mode of action of miRNAs in the cell are
reasonably well understood and recent advances have
yielded promising results for future miRNA-based thera-
pies. MiRNAs have been detected in bodily fluids such as
blood, saliva or urine [46]. Although the exact function and
origin of those extracellular miRNA are still debated, these
molecules seem to function as novel messengers allowing
cells in the body to communicate with other cells [47]. A
special class of extracellular miRNAs are called circulating
miRNAs. They are found in plasma or serum and are
theorized to be involved in cell to cell signaling [48]. Since
circulating miRNAs can be easily obtained through a blood
draw, they are promising targets to investigate as potential
liquid biopsy markers. For example, if a marker profile
could be linked to an increased risk of developing AMD,
this could be used as a minimally invasive screening tool to
monitor treatment success. Furthermore, dysregulated
miRNAs could potentially be a treatment option them-
selves by using miRNA mimics or antagomirs to modulate
miRNA levels in the cell [49, 50].
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Four studies published between 2014 and 2016 analyzed
the circulating miRNA expression profiles of AMD
patients (Table 1; Fig. 2). Of note, there is little overlap in
the findings between the four studies. Although some
miRNAs were found in several studies, they do not nec-
essarily agree on the orientation of the effect. For example,
miR-424-5p was found to be dysregulated in two studies,
one study found the miR-424-5p to be downregulated in
patients with late-stage NV AMD (p cor-
rected = 9.6 9 10-3) [51] and no significant differences
between the expression of miR-424-5p in GA AMD
patients and controls. The authors noted, however, that the
miR-424-5p expression was significantly higher in GA
AMD patients compared to NV AMD patients (p cor-
rected\0.005). A second study, published almost one year
later, showed the opposite results. They found that miR-
424–5p was upregulated in NV and GA AMD patients
versus controls (p\ 0.0001) [52]. Both studies agreed on
the finding that miR-424-5p expression is higher in GA
than NV AMD. The studies used a similar approach, a
discovery study to find potential candidates and a valida-
tion study relying on quantitative (q)RT-PCR to confirm
the candidates’ association with AMD, and recruited sim-
ilarly sized cohorts. Their approach differed in the method
used for the discovery study [next-generation sequencing
(NGS) vs. qRT-PCR], but this can hardly explain the dif-
ferent direction of dysregulation which each study con-
firmed by using qRT-PCR. A partial explanation for these
discrepancies may lie in the patient inclusion criteria, as the
first study included late-stage NV AMD patients, some of
whom had received anti-VEGF therapy, while the second
report used newly diagnosed patients, who had not received
any therapy prior to their recruitment for the study. Further,
some controls in the first study suffered from glaucoma,
whereas in the second study, only samples from people
without ocular abnormalities were included.
These inconsistencies are not unique to those two studies,
in fact all four studies varied in the methods applied to
quantifymiRNAs, normalizing for qRT-PCRexpression and
profiling of patients included. Since the reported results
differ substantially, the possibility that the different results
could be due to methodological characteristics needs to be
considered. Additionally, some studies had small sample
sizes (13–33 patients, and as many controls), which draws
into question the statistical power issue and consequently the
validity of the conclusions. Conversely, two of the studies
had large sample sizes (188–300 patients, and 147–200
controls). This, and the fact that AMD profiling studies of
AMD mouse models revealed some overlapping results,
appears reasonable to not entirely disregard the patient
cmiRNA profiling studies, but instead to consider these
results as preliminary, and to enjoy them with caution.
A more promising candidate may be miR-301. One study
found the miR-301-3p arm to be downregulated in NV AMD
[51], whereas a second study found the miR-301-5p arm to be
upregulated in NV and GAAMD [52]. InmiRNA biogenesis,
Fig. 1 Word-cloud representation of words found in abstracts related
to the search term ‘‘miRNAs and AMD’’. All words with an
occurrence greater than 4 are plotted and their relative abundance is
indicated by the size of the respective word. Figure was plotted with
Tagxedo (http://www.tagxedo.com/app.html) using words from the
abstracts of 21 publications related to miRNAs in AMD
[51, 52, 56, 57, 71, 73–75, 77, 82, 89, 90, 99, 103–110]
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the 5p and 3p arms of a mature miRNA are processed from a
long precursor miRNA [53]. The 5p and 3p arms are sepa-
rated, the guide strand is incorporated into the RNA-induced
silencing complex, RISC, and subsequently becomes a func-
tional gene inhibitor. The second strand, termed the comple-
mentary strand, usually becomes degraded. These two studies
Table 1 Circulating miRNAs
dysregulated in AMD
cmiRNA Family FCb Tissue Pathology Source
hsa-Let-7a let-7 6.74; 2.7c Serum NV and GA AMD [52]
hsa-Let-7ca let-7 o.p. Plasma NV AMD [103]
hsa-miR-106a-5p mir-17 3.45 Plasma NV AMD [103]
hsa-miR-106b-5p mir-17 -1.5 Plasma NV AMD [57]
hsa-miR-139-3p mir-139 o.p. Plasma NV AMD [103]
hsa-miR-140-3p mir-140 -2.81 Plasma NV AMD [103]
hsa-miR-146a-5p mir-146 2.5 Plasma NV AMD [57]
hsa-miR-146b-5p mir-146 -8.68 Plasma NV AMD [103]
hsa-miR-152-3p mir-148 -1.7 Plasma NV AMD [57]
hsa-miR-17-5p mir-17 2.77 Plasma NV AMD [103]
hsa-miR-192-5p mir-192 -3.54 Plasma NV AMD [103]
hsa-miR-20a-5p mir-17 2.02 Plasma NV AMD [103]
hsa-miR-212-3p mir-132 o.p. Plasma NV AMD [103]
hsa-miR-21-5p mir-21 -3.09 Plasma NV AMD [103]
hsa-miR-223-3p mir-223 1.65 Plasma NV AMD [103]
hsa-miR-24-3p mir-24 1.58 Plasma NV AMD [103]
hsa-miR-25-3p mir-25 -1.84 Plasma NV AMD [103]
hsa-miR-26b-5p mir-26 o.p. Plasma NV AMD [103]
hsa-miR-27b-3p mir-27 o.p. Plasma NV AMD [103]
hsa-miR-29a-3p mir-29 o.p. Plasma NV AMD [103]
hsa-miR-301-3p mir-130 -0.318 Plasma NV AMD [51]
hsa-miR-301-5p mir-130 3.94; 4.47c Serum NV and GA AMD [52]
hsa-miR-3121a mir-3121 2.85; 8.7c Serum NV and GA AMD [52]
hsa-miR-324-3p mir-324 o.p. Plasma NV AMD [103]
hsa-miR-324–5p mir-324 o.p. Plasma NV AMD [103]
hsa-miR-335-5p mir-335 -7.00 Plasma NV AMD [103]
hsa-miR-342-3p mir-342 -2.65 Plasma NV AMD [103]
hsa-miR-361-5p mir-361 -0.373 Plasma NV AMD [51]
hsa-miR-374a-5p mir-374 -12.92 Plasma NV AMD [103]
hsa-miR-410a mir-154 -9.84 Plasma NV AMD [103]
hsa-miR-424-5p mir-322 -0.338 Plasma NV AMD [51]
hsa-miR-424-5p mir-322 3.28; 3.97c Serum NV and GA AMD [52]
hsa-miR-4258a unknown 8.55; 2.6c Serum NV and GA AMD [52]
hsa-miR-532-3p mir-188 o.p. Plasma NV AMD [103]
hsa-miR-574-3p mir-574 -2.44 Plasma NV AMD [103]
hsa-miR-660-5p mir-188 -3.39 Plasma NV AMD [103]
hsa-miR-661a mir-661 1.96; 9.05c Serum NV and GA AMD [52]
hsa-miR-744-5p mir-744 o.p. Plasma NV AMD [103]
hsa-miR-889a mir-889 3; 8.9c Serum NV and GA AMD [52]
miR438a unknown 3.3; 3.3c Serum NV and GA AMD [52]
FC fold change, AMD age-related macular degeneration, miRNA micro RNA, cmiRNA circulating micro
RNA, GA AMD graphic atrophy AMD, NV AMD neovascularization AMD
a Mature miRNA strand unknown/not mentioned
b o.p. miRNA was only expressed in the patient group
c Fold change for NV AMD; fold change for GA AMD
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may indicate that miR-301-5p is a negative gene regulator in
AMD, while miR-301-3p is subsequently degraded, and
therefore downregulated in the patient.
In some cases the 5p and 3p arms can be directly cor-
related with another [54, 55]. Unfortunately, most publi-
cations do not specify which miRNA arm was studied,
making it difficult to interpret their results. Furthermore,
multiple members of the same miRNA families have been
found in the various studies, i.e. let-7 and let-7c of the let-7
family, and miR-106a and b of the miR-17 family, among
others. This is not as helpful as it might appear. MiRNAs
are grouped into families based on similar sequence or their
location in the genome, not based on their function. So,
even though two members of the mir-188 family are
indicated to be dysregulated in AMD, it still is difficult to
draw conclusions from this.
2.2 MiRNA Dysregulation in AMD Ocular Tissue
To date, three studies profiled miRNA from samples of
AMD retinae and RPE cells, and one study reported
miRNA measurements from vitreous humor (VH) of AMD
patients (Table 2; Fig. 2). MiR-146a was found to be
upregulated in both forms of AMD, and in different tissue.
One study showed the miRNA to be upregulated in the
retina of GA AMD patients [56], whereas a second study
found a 3.0-fold increase in the VH of NV AMD patients
[57]. Both studies used similar sample sizes (12–13
patients and 9–13 controls), and methods to assess miRNA
levels. The second study further discovered an upregulation
of the miRNA in the plasma of NV AMD patients. Inter-
estingly, a third group confirmed the upregulation of miR-
146a in the serum of NV and GA AMD patients, although
these findings were not validated using qRT-PCR [52].
Unfortunately, two of these studies did not specify whether
they analyzed the 5p or 3p arm [52, 56].
MiR-146a is a well characterized small RNA and has
been linked to progressive, age-related, inflammatory
neurodegenerative disorders [58]. MiR-146a is theorized to
modulate innate immune responses, inflammation, and the
microglial activation state, although it is not yet clear
whether the induction of miR-146a is protective or detri-
mental to the cell. It is under transcriptional control by
nuclear factor-kappaB (NF-jB), and has been found to be
upregulated by reactive oxygen species, pro-inflammatory
cytokines, and amyloid peptides. Multiple studies have
established that upregulation of miR-146a in stressed
human neural cells such as astroglia and microglia, results
in the downregulation of complement factor H (CFH)
[59, 60]. CFH is a major repressor of the innate-immune
and inflammatory response, and one of the key players in
AMD pathogenesis [58, 61, 62]. It has been suggested that
the upregulation of miR-146a has detrimental effects and
promotes the pathogenesis of AMD [61]. There is evidence
suggesting the opposite behavior as MiR-146a has been
shown to interfere with interleukin-1-receptor-associated
kinase-1 (IRAK1) and TNF receptor-associated factor 6
(TRAF6) [63, 64] as well as directly down-regulating
interleukin-6 (IL-6) [57, 65]. IRAK1 and TRAF6 are
known modulators of the NF-jB pathway, and their
translational repression inhibits pro-inflammatory cytokine
signaling [57, 66–68]. IL-6 acts as a pro-inflammatory
cytokine, and is routinely used in the diagnosis of sepsis
[69]. Since IL-6 is associated with progression of NV
[64, 70] miR-146a may be a protective regulator of
inflammation in NV AMD [57]. However, as the effect of
miR-146a is not fully protective nor fully detrimental for
AMD, the molecule is unlikely a good candidate for a
therapeutic intervention.
A closely related small RNA to miR-146a, is miR-146b-
5p, which is also theorized to be a negative regulator of
inflammation, although it has not been characterized nearly
as well as miR-146a [71]. MiR-146b is known to target
IRAK1 and TRAF6 thereby inhibiting pro-inflammatory
Fig. 2 Interaction between AMD related miRNAs and genes, path-
ways and tissues. We selected four miRNAs (plotted in blue) with the
most evidence for an involvement in AMD and used Tarbase v7.0
[111] to extract genes (plotted in yellow) with validated interactions
with those miRNAs. Genes that are regulated by at least three out of
four miRNAs were used to search for significantly enriched pathways
using WebGestalt [112]. Pathways containing at least six of these
genes and being significantly enriched (Bonferroni corrected
p value\0.01) are plotted in purple. The role of the miRNAs in
AMD pathology was evaluated in different tissues and/or mouse
models (plotted in green)
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cytokine signaling [63, 65, 71, 72]. One study showed that
the expression of miR-146a and miR-146b is highly
induced by a combination of pro-inflammatory cytokines
(IFN-c, TNF-a, and IL-1b) in human RPE cells [71].
Conversely, miR-146b was shown to be downregulated in
NV AMD plasma. Since both miRNAs bind similar targets,
this could be a method of harnessing an immune reaction.
2.3 Dysregulated miRNA in AMD Models Provide
Clues to Understanding the Function of miRNA
Dysregulated in AMD
Multiple studies have profiled miRNAs in RPE cells of
mice and rats in experimental models meant to mimic
characteristic pathological changes seen in AMD patients
(Supplementary Table 1; Fig. 2). These studies have
shown a combined total of 176 miRNAs to be dysregu-
lated. Fourteen of these miRNAs were also dysregulated in
the same direction in AMD patients, which makes them
exciting contenders for further research (Table 3). Impor-
tantly, the miRNA with the highest number of studies
supporting its involvement in AMD is miR-146a. Two
studies performed in patients, and three studies performed
in human RPE cells or in mouse retinae revealed a miR-
146a upregulation, although one study indicated this
miRNA species to be downregulated after oxygen-induced
retinopathy (OIR) [56, 57, 71, 73–75]. Although techni-
cally not an AMD model, OIR is a well-established pro-
tocol used to study hyperoxia-induced retinal
neovascularization and inflammation in mice, two well-
known characteristics of AMD [76, 77]. One upregulated
miRNA in an OIR model, and oxidative stress model in
RPE cells, as well as in NV AMD plasma was miR-17, a
regulator of angiogenesis [78]. MiR-17 targets several pro-
angiogenic genes, and the inhibition of miR-17 along with
miR-20 increased the number of perfused vessels in
Matrigel plugs [78]. Besides its antiangiogenic activity,
miR-17 was recently shown to be anti-apoptotic as well
[79]. Pretreatment with miR-17 significantly prevented the
norepinephrine-induced apoptosis of cardiomyocytes, by
inhibiting apoptotic protease activating factor 1 (Apaf-1), a
facilitator of apoptosome formation. miR-17 is part of the
miR-17-92 cluster, which is a negative regulator of
angiogenesis, and encodes miR-17, -18a, -19a/b, -20a, and
miR-92a [50]. Of the other members of this cluster, only
miR-92a was upregulated in RPE cells after oxidative
stress, and in mouse retinae after OIR [80]. miR-92a was
not dysregulated in AMD patients. MiR-92a is a well-
studied miRNA which also regulates angiogenesis. First,
Bonauer et al. [50] showed the miRNA was upregulated in
a hind limb mouse ischemia model in response to ischemic
injury. The authors then systemically injected mice with a
miR-92 antagomir before inducing ischemia, and showed
that these mice had improved functional recovery of
ischemic limbs, due to improved neovascularization and
perfusion [50]. Similarly, treating mice with the miR-92
antagomir after inducing an acute myocardial infarction,
resulted in reduced infarct size and improved left ventric-
ular systolic and diastolic function [50]. miR-92a was
significantly reduced in patients with coronary artery dis-
ease, a major risk factor for acute myocardial infarction
[81].
Another miRNA which may regulate neovascularization
and apoptosis is miR-106b, which was downregulated in
NV AMD plasma and VH, and in RPE cells after oxidative
stress [57, 82]. MiR-106b-25 cluster knockout mice
Table 2 MiRNA dysregulated
in ocular tissue of AMD patients
miRNA Family FCc Tissue Pathology Source
miR-106b-5p miR-17 -0.23 Vitreous humor NV AMD [57]
miR-125ba miR-10 ? Retina GA AMD [56]
miR-146aa miR-146 2.1 Retina GA AMD [56]
miR-146a-5p miR-146 3.02 Vitreous humor NV AMD [57]
miR-152-3p miR-148 -0.33 Vitreous humor NV AMD [57]
miR-155a miR-155 ? Retina GA AMD [56]
miR-184a miR-184 – RPE cell cultureb AMD [89]
miR-23aa miR-23 – Macular RPE cell cultureb AMD [104]
miR-34aa miR-34 6.3 Retina and macula GA AMD [56]
miR-9a miR-9 ? Retina GA AMD [56]
FC fold change, AMD age-related macular degeneration, miRNA micro RNA, cmiRNA circulating micro
RNA, GA AMD graphic atrophy AMD, NV AMD neovascularization AMD, RPE retinal pigment epithelium
a Mature miRNA strand unknown/not mentioned
b Primary culture of human RPE isolated from eyes of AMD donors
c A ‘‘?’’ indicates miRNA upregulated/higher levels and a ‘‘-’’ indicates miRNA downregulated/lower
levels
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showed impaired neovascularization after hind limb
ischemia in mice [83]. This effect was confirmed in a study
which induced cerebral ischemia in mice which had
received a miR-106b antagomir, and observed decreased
infarct volume and neuronal injury [84]. The same miR-
106b antagomir-protected cells derived from a pheochro-
mocytoma of the rat adrenal medulla (PC12) against glu-
tamate-induced apoptosis and oxidative damage, as
evidenced by decreased lactate dehydrogenase release, and
enhanced superoxide dismutase activity [84]. MiR-106b
showed an age-dependent expression, and was downregu-
lated in serum from patients aged 70 versus 22 years [85].
With neovascularization as the hallmark of NV AMD, it
is not surprising that many of the miRNAs associated with
the disease have also been linked to angiogenesis. MiR-
125b was upregulated in patient retinae, in mouse retinae
after OIR, and in ARPE-19 cells under oxidative stress
[56, 75, 82]. Overexpression of miR-125b was negatively
correlated with VEGF mRNA, and inhibited tumor-in-
duced angiogenesis in ovarian cancer cells [86]. In brain
endothelial cells (ECs), miR-125b overexpression resulted
in a trend towards reduced tubule length [87]. This inverse
correlation between miR-125b and in vitro tube formation
by ECs was confirmed by Muramatsu et al. [88] who the-
orized that prolonged overexpression of miR-125b could
result in blood vessel regression due to a transient proan-
giogenic stimulation of miR-125b induction in EC cells.
MiR-184was downregulated in primary culture of human
RPE cells isolated from eyes of AMD donors and in OIR
mouse retinae [77, 89, 90]. One of the studies showed that
miR-184 negatively regulates Wnt signaling in OIR retinae,
a conserved intracellular signaling pathway also involved in
regulating angiogenesis and inflammation [77]. This inter-
action was confirmed by other findings that showed corneal
neovascularization induced by suture was ameliorated by
topical administration of miR-184 in rats [91]. Inhibition of
miR-184 significantly reduced phagocytosis efficiency in
adult RPE cells [89]. Phagocytosis is crucial for the main-
tenance of photoreceptors, and an age-related decline in
phagocytosis is thought to contribute to AMD [89, 92, 93].
Interestingly, a group studying ocular Chlamydia tra-
chomatis infection demonstrated that miR-184 and miR-155
had a direct relationship with the degree of clinical inflam-
mation, where miR-184 was downregulated, and miR-155
was upregulated as the severity increased [94]. This inverse
relationship may also be true in AMD, since miR-184 was
downregulated in AMD RPE cell culture, while miR-155
was upregulated in AMD retina and macula [56, 89].
MiR-424, which was dysregulated in opposite directions
in two independent studies with AMD patients was
upregulated in OIR mouse retinae [90]. This may indicate
that the upregulation is a true effect, although the evidence
of upregulation in OIR mouse retinae is far from
conclusive. OIR mimics two key traits of AMD such as
inflammation and angiogenesis. In AMD, however, the
macula is primarily affected, and mice do not have a
macula. Therefore, information gained from mouse models
of AMD should be considered with caution.
2.4 Manipulation of miRNA in AMD Mouse Models
Ameliorate Damage
Multiple studies have manipulated miRNA levels in vivo
following a pathologic insult and tested the effect. MiRNA
were either over-expressed using a pre-miR or miR-mimic,
or under-expressed using an antisense-miR or a knockout
mouse. Subsequently, neovascularization was quantified
and many miRNAs were shown to ameliorate the inflicted
damage (Table 4; Fig. 2). Unfortunately, most of the
miRNAs tested were not homologous to those which were
dysregulated in the AMD profiling studies (see above), but
there are two that overlap, miR-155 and miR-184.
As mentioned above, strong data suggest that miR-184
is involved in angiogenesis. The studies showed that miR-
184 is downregulated in OIR mouse retinae, and one of the
groups also showed that intraocular injection with pre-
miR-184 reduced retinal neovascularization in OIR mice
[90]. The authors also tested the miRNA in the most widely
accepted NV AMD model, the laser-induced choroidal
neovascularization [95–98]. This model relies on laser
injury to perforate Bruch’s membrane, resulting in sub-
retinal blood vessel recruitment from the choroid, recapit-
ulating the main characteristic of NV AMD [95]. Of note,
in this context treatment with pre-miR-184 failed to reduce
the area of choroidal NV.
A far more complex candidate is miR-155 as it regulates
not only angiogenic but also inflammatory responses in the
retina. MiR-155 was upregulated in GA AMD retina and
macula, in OIR mouse retina, and in rat retinas after light-
induced retinal degeneration [56, 75, 99]. Yan et al. [75]
subjected miR-155 knockout mice to OIR, but found no
protective effects against OIR provided by miR-155 defi-
ciency. Instead, it induced rapid revascularization and
prevented the development of aberrant neovascularization.
Next, the authors demonstrated that intraocular injection of
a miR-155 mimic in WT mice (postnatal day 3) delayed
migration of the regularly and radially expanding superfi-
cial capillary plexus and hindered advancement toward the
retinal edge. To elucidate the effect of miR-155 on
inflammation, they first showed that miR-155 knockout
mice had significantly reduced numbers of microglia. miR-
155-deficient mice showed a decreased expression of
mitochondrial translocator protein, a selective marker of
microglia in their highly reactive state [100], but an
increased expression of CD200R, which blocks pro-in-
flammatory activation in microglial cells [75, 101]. The
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OIR miR-155 knockout mice showed reduced translocator
protein (TPSO) and inflammatory cytokines [75]. It is of
note, however, that miR-155 has been shown to have a cell-
type specific function. The growth of six breast cancer cell
lines showed a wide range of sensitivities when transfected
with a miR-155 mimic [102]. MiR-155 may have a similar
cell-type specific function in the microglia, endothelial
cells, RPE cells, or some of other cell types implicated in
AMD pathogenesis.
3 Conclusions
Taken together, increasing research efforts on small RNAs
suggests that dysregulated miRNAs may regulate key
aspects of AMD pathology. While data on circulating
miRNA in AMD are still scarce, findings on dysregulated
ocular miRNA show more promise. For example, mir-146a
and miR-155 are regulators of inflammation and microglial
activation state in response to stress, and are both dysreg-
ulated in AMD retinae. Furthermore, angiogenesis and
response to varying oxygen levels is likely modulated by
miR125b, and miR-17, which may also regulate apoptosis.
These key candidate miRNAs could be useful as novel
therapeutic approaches in AMD, as exemplified by miR-
155 which was shown to modulate damage in AMD mouse
models in vivo. Still, studies in mouse models are not ideal
in the long term, and must be complemented by compre-
hensive studies establishing miRNA profiles in AMD
development and progression.
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